The CASP9 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 143B osteosarcoma line, carrying targeted disruption of the CASP9 gene. This genome-edited pool provides a loss-of-function model for caspase-9, the initiator caspase of the intrinsic apoptosis pathway, enabling robust population-level studies of mitochondrial apoptosis signaling.
The 143B human osteosarcoma cell line is a widely used bone cancer model with high tumorigenic and metastatic potential in vivo. It expresses key apoptosis regulators including BAX, BAK, BCL-2, and BCL-XL, and retains wild-type TP53, facilitating physiologically relevant p53-mediated apoptotic responses. These features make 143B an ideal host for interrogating mitochondrial outer membrane permeabilization (MOMP) and caspase activation in a cancer context.
CASP9 encodes caspase-9, which is activated within the cytochrome c/APAF1 apoptosome and subsequently cleaves executioner caspases-3 and -7 to execute apoptosis. Upstream, mitochondrial outer membrane permeabilization by BAX/BAK releases cytochrome c, a process inhibited by anti-apoptotic BCL-2 and BCL-XL and promoted by p53-inducible BH3-only proteins PUMA and NOXA. Active caspase-9 is directly inhibited by XIAP, whose binding is antagonized by SMAC/Diablo released from mitochondria, and is further modulated by survival kinases such as Akt and PKA, as well as Hsp70, which interferes with apoptosome assembly. In the knockout model, the absence of caspase-9 disrupts intrinsic apoptosis signaling, preventing proteolytic activation of downstream substrates including PARP, ICAD, and Bid.
In 143B osteosarcoma, CASP9 ablation models apoptotic resistance, a hallmark of chemoresistant bone tumors. The polyclonal knockout cells enable dissection of alternative death pathways when the intrinsic route is blocked, such as death receptor-mediated caspase-8 activation or necroptosis. They also allow evaluation of therapeutic strategies like SMAC mimetics that bypass caspase-9 dependence.
These polyclonal knockout cells support diverse apoptosis research applications, including drug screening for caspase-9-independent apoptosis inducers and mechanistic studies of mitochondrial dysfunction. Assays commonly employed include Western blot analysis of caspase-9 and caspase-3 cleavage, Annexin V/PI flow cytometry, TUNEL assay, and JC-1 mitochondrial membrane potential measurement. They are also applicable to neurodegeneration research, where caspase-9 is implicated in Alzheimer’s and Parkinson’s disease. For further details, contact Ascent Research.
